UNLABELLED: Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types. The goal of this study was to develop a PET tracer for imaging of TF expression in pancreatic cancer. METHODS: ALT-836, a chimeric antihuman TF monoclonal antibody, was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) and labeled with (64)Cu. To compare the TF binding affinity of ALT-836 and NOTA-ALT-836, flow cytometry analysis was performed in 3 pancreatic cancer cell lines with different expression levels of TF (from low to high: PANC-1, ASPC-1, and BXPC-3). PET, biodistribution, blocking, and histology studies were performed on pancreatic tumor-bearing mice to evaluate the ability and specificity of (64)Cu-NOTA-ALT-836 to target TF in vivo. RESULTS: There was no difference in TF binding affinity between ALT-836 and NOTA-ALT-836. (64)Cu-labeling was achieved with high yield and specific activity. Serial PET revealed that the uptake of (64)Cu-NOTA-ALT-836 in BXPC-3 tumors (high TF expression) was 5.7 ± 1.8, 10.4 ± 0.8, and 16.5 ± 2.6 percentage injected dose per gram at 4, 24, and 48 h after injection, respectively (n = 4), significantly higher than that in the PANC-1 and ASPC-1 tumors. Biodistribution data as measured by γ-counting were consistent with the PET findings. Blocking experiments and histology further confirmed the TF specificity of (64)Cu-NOTA-ALT-836. CONCLUSION: Herein we report the first successful PET imaging of TF expression. Persistent and TF-specific uptake of (64)Cu-NOTA-ALT-836 was observed in pancreatic cancer models.
UNLABELLED: Upregulation of tissue factor (TF) expression leads to increased patient morbidity and mortality in many solid tumor types. The goal of this study was to develop a PET tracer for imaging of TF expression in pancreatic cancer. METHODS:ALT-836, a chimeric antihuman TF monoclonal antibody, was conjugated to 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) and labeled with (64)Cu. To compare the TF binding affinity of ALT-836 and NOTA-ALT-836, flow cytometry analysis was performed in 3 pancreatic cancer cell lines with different expression levels of TF (from low to high: PANC-1, ASPC-1, and BXPC-3). PET, biodistribution, blocking, and histology studies were performed on pancreatic tumor-bearing mice to evaluate the ability and specificity of (64)Cu-NOTA-ALT-836 to target TF in vivo. RESULTS: There was no difference in TF binding affinity between ALT-836 and NOTA-ALT-836. (64)Cu-labeling was achieved with high yield and specific activity. Serial PET revealed that the uptake of (64)Cu-NOTA-ALT-836 in BXPC-3 tumors (high TF expression) was 5.7 ± 1.8, 10.4 ± 0.8, and 16.5 ± 2.6 percentage injected dose per gram at 4, 24, and 48 h after injection, respectively (n = 4), significantly higher than that in the PANC-1 and ASPC-1 tumors. Biodistribution data as measured by γ-counting were consistent with the PET findings. Blocking experiments and histology further confirmed the TF specificity of (64)Cu-NOTA-ALT-836. CONCLUSION: Herein we report the first successful PET imaging of TF expression. Persistent and TF-specific uptake of (64)Cu-NOTA-ALT-836 was observed in pancreatic cancer models.
Authors: Hao Hong; Hélène A Benink; Yin Zhang; Yunan Yang; H Tetsuo Uyeda; Jonathan W Engle; Gregory W Severin; Mark G McDougall; Todd E Barnhart; Dieter H Klaubert; Robert J Nickles; Frank Fan; Weibo Cai Journal: Am J Transl Res Date: 2011-07-28 Impact factor: 4.060
Authors: Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Ilaria Grassi; Cristina Nanni; Vincenzo Allegri; Joshua James Morigi; Gian Carlo Montini; Paolo Castellucci; Stefano Fanti Journal: Am J Nucl Med Mol Imaging Date: 2011-12-15
Authors: Peter E Morris; Jay S Steingrub; Bee Y Huang; Shamay Tang; Patrick M Liu; Peter R Rhode; Hing C Wong Journal: BMC Pulm Med Date: 2012-02-16 Impact factor: 3.317
Authors: Haiming Luo; Hao Hong; Michael R Slater; Stephen A Graves; Sixiang Shi; Yunan Yang; Robert J Nickles; Frank Fan; Weibo Cai Journal: J Nucl Med Date: 2015-04-03 Impact factor: 10.057
Authors: Hao Hong; Yongjun Yan; Sixiang Shi; Stephen A Graves; Lazura K Krasteva; Robert J Nickles; Min Yang; Weibo Cai Journal: Mol Pharm Date: 2015-01-20 Impact factor: 4.939
Authors: Reinier Hernandez; Christopher G England; Yunan Yang; Hector F Valdovinos; Bai Liu; Hing C Wong; Todd E Barnhart; Weibo Cai Journal: J Control Release Date: 2017-08-24 Impact factor: 9.776
Authors: Haiming Luo; Christopher G England; Shreya Goel; Stephen A Graves; Fanrong Ai; Bai Liu; Charles P Theuer; Hing C Wong; Robert J Nickles; Weibo Cai Journal: Mol Pharm Date: 2017-03-24 Impact factor: 4.939
Authors: Sixiang Shi; Hao Hong; Hakan Orbay; Stephen A Graves; Yunan Yang; Jakob D Ohman; Bai Liu; Robert J Nickles; Hing C Wong; Weibo Cai Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-24 Impact factor: 9.236
Authors: Sixiang Shi; Hakan Orbay; Yunan Yang; Stephen A Graves; Tapas R Nayak; Hao Hong; Reinier Hernandez; Haiming Luo; Shreya Goel; Charles P Theuer; Robert J Nickles; Weibo Cai Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Haiming Luo; Christopher G England; Sixiang Shi; Stephen A Graves; Reinier Hernandez; Bai Liu; Charles P Theuer; Hing C Wong; Robert J Nickles; Weibo Cai Journal: Clin Cancer Res Date: 2016-03-29 Impact factor: 12.531
Authors: Jesse Pulido; Maria de Cabrera; Adam J Sobczak; Alejandro Amor-Coarasa; Anthony J McGoron; Stanislaw F Wnuk Journal: Bioorg Med Chem Date: 2018-10-12 Impact factor: 3.641